Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
about
Toll-like Receptors in Ovarian Cancer as Targets for ImmunotherapiesResiquimod and polyinosinic-polycytidylic acid formulation with aluminum hydroxide as an adjuvant for foot-and-mouth disease vaccine.Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex FormationTrial Watch: Experimental Toll-like receptor agonists for cancer therapyImmuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer.Combinations of TLR ligands: a promising approach in cancer immunotherapy.Immune therapy for ovarian cancer: promise and pitfalls.Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.Modes of action of TLR7 agonists in cancer therapy.TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.Anti-tumor Activity of Toll-Like Receptor 7 Agonists.Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything.Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model.Stromal cells in breast cancer as a potential therapeutic target.
P2860
Q26861234-4A06547D-F0A2-4443-BA80-AFDED67553ADQ31147070-1D14F66E-B06F-4B11-A8DA-5D63A5A4C6AAQ34056568-26AD75AB-6A10-4058-8E3D-F92FC263DDF7Q36182299-2B7AEC77-9D66-49F0-9933-C750E3D812ECQ36194849-24E8EE95-809E-438C-9539-50FE54C85867Q36248464-6ABE3E3B-905C-47D3-8B5A-93B82E15A8F4Q37383587-01D98F54-F0D8-49E7-BA2F-595C1CAAA5A9Q37873928-4A4FD044-014F-421E-8AD2-3859B0AEC04AQ37873932-AD4AEFFF-3D07-49F3-8A6D-5ED4D68DCD82Q38271879-CFF152B3-1922-4353-8279-ABF3586EE290Q38862113-DAAA5FFC-2583-4D04-B742-14FAC5E93614Q39377049-F09DB7A0-27BA-4035-B271-A6D241DC483FQ41954343-D770AFF4-CF91-4B07-AE84-500F6F2A57FAQ45062234-15105253-5F7D-4515-8F9F-7A473D22C602Q55016792-7DA4A726-5FE4-42C4-83FC-8F64E634A1FB
P2860
Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@ast
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@en
type
label
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@ast
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@en
prefLabel
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@ast
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@en
P2093
P2860
P1476
Toll-like receptor-7 agonist a ...... t, ovarian, and cervix cancers
@en
P2093
Angela Panoskaltsis-Mortari
Brenda Weigel
Julie Curtsinger
Levi S Downs
Linda F Carson
Melissa A Geller
Patricia L Judson
Peter A Argenta
Sarah Cooley
P2860
P2888
P304
P356
10.1007/S00262-010-0914-1
P577
2010-09-05T00:00:00Z
P6179
1036706478